Biotech Values

[DewDiligence]

MNTA – Please see #msg-37030489 for the rationale of the M402 cancer program.

If FoB-enabling legislation were to flounder in Congress, I could see a step-up in R&D for M402, and MNTA’s small capital raise in December could end up looking smart. (Of course, MNTA will be rolling in dough in the FDA comes through with a single-company approval of generic Lovenox.)